IP Library Granted Patent US 9,535,074
Granted Patent B2
US 9,535,074 · App. 14/843,285 · Granted Jan 3, 2017

Immunoassay for soluble PD-L1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,535,074
App. No.
14/843,285
Granted
Jan 3, 2017
Kind
B2
Abstract

The present disclosure describes two matched antibody pairs for use in a sandwich immunoassay for detecting and quantifying soluble PD-L1 in liquid samples, as well as an electrochemiluminescence sandwich immunoassay that has been optimized and validated with one of the matched pairs.

Claims (28)

1. A kit for detecting soluble human Programmed Cell Death 1 Ligand 1 (shPD-L1) in a liquid sample, wherein:

(a) the kit comprises a capture binding molecule and a detector binding molecule;

(b) the capture reagent is an isolated antibody or antigen binding fragment thereof that specifically binds shPD-L1 and comprises three light chain CDRs of SEQ ID NOs: 7, 8 and 9 and three heavy chain CDRs of SEQ ID NOs: 13, 14 and 15; and

(c) the detector binding molecule is an isolated antibody or antigen binding fragment thereof that is capable of specifically binding to shPD-L1 molecules that are complexed with the capture binding molecule and which comprises: (a) three light chain CDRs of SEQ ID NOs: 19, 20 and 21 and three heavy chain CDRs of SEQ ID NOs: 25, 26 and 27; or (b) three light chain CDRs of SEQ ID NOs: 31, 32 and 33 and three heavy chain CDRs of SEQ ID NOs: 37, 38 and 39.

2. The kit of claim 1 , wherein the capture binding molecule is immobilized on a solid support and the detector binding molecule comprises a detectable label.

3. The kit of claim 2 , wherein the capture binding molecule is biotinylated.

4. The kit of claim 1 , wherein the detector binding molecule is labeled with an amine reactive, N-hydroxysuccinimide ester.

5. The kit of claim 1 , wherein the kit comprises a solid support that is coated with streptavidin.

6. The kit of claim 1 , wherein the capture binding molecule is an antibody which comprises a light chain variable region of SEQ ID NO:1 and a heavy chain variable region of SEQ ID NO:2.

7. The kit of claim 1 , wherein the detector binding molecule is an antibody which comprises:

(a) a light chain variable region of SEQ ID NO:3 and a heavy chain variable region of SEQ ID NO:4; or

(b) a light chain variable region of SEQ ID NO:5 and a heavy chain variable region of SEQ ID NO:6.

8. The kit of claim 1 , wherein the detector binding molecule is an antibody which comprises a light chain variable region of SEQ ID NO:3 and a heavy chain variable region of SEQ ID NO:4.

9. An assay for detecting sPD-L1 in a liquid sample which comprises:

(a) providing a solid substrate that is coated with a capture binding molecule, wherein the capture binding molecule is an isolated antibody or antigen binding fragment thereof that specifically binds sPD-L1 and comprises three light chain CDRs of SEQ ID NOs: 7, 8 and 9 and three heavy chain CDRs of SEQ ID NOs: 13, 14 and 15;

(b) incubating the sample with the solid substrate under conditions suitable for formation of a first complex between the capture binding molecule and sPD-L1 in the sample,

(c) washing the solid substrate at least once with a wash buffer to remove the unbound sPD-L1,

(d) incubating the solid substrate with a detector binding molecule under conditions suitable for formation of a second complex between the captured sPD-L1 and the detector binding molecule, wherein the detector binding molecule is an isolated antibody or antigen binding fragment thereof that is capable of specifically binding to shPD-L1 molecules that are complexed with the capture binding molecule and which comprises: (i) three light chain CDRs of SEQ ID NOs: 19, 20 and 21 and three heavy chain CDRs of SEQ ID NOs: 25, 26 and 27; or (ii) three light chain CDRs of SEQ ID NOs: 31, 32 and 33 and three heavy chain CDRs of SEQ ID NOs: 37, 38 and 39;

(e) washing the solid substrate at least once with the wash buffer to remove the unbound detector binding molecule, and

(f) detecting the second complex.

10. The assay of claim 9 , wherein the capture binding molecule is biotinylated and the solid substrate is coated with streptavidin or avidin.

11. The assay of claim 9 , wherein the capture binding molecule is biotinylated and the solid substrate is a 96 well microtiter plate coated with streptavidin.

12. The assay of claim 9 , wherein the detector binding molecule is labeled with an amine reactive, N-hydroxysuccinimide ester.

13. The assay of claim 9 , wherein the capture binding molecule is an antibody which comprises a light chain variable region of SEQ ID NO:1 and a heavy chain variable region of SEQ ID NO:2 and the detector binding molecule is an antibody which comprises a light chain variable region of SEQ ID NO:3 and a heavy chain variable region of SEQ ID NO:4.

14. The assay of claim 9 , wherein the assay comprises assaying a set of standards having sPD-L1 concentrations of about 1.1 pg/ml, 3.3 pg/ml, 9.9 pg/ml, 29.6 pg/ml, 88.9 pg/ml, 266.7 pg/ml, 800 pg/ml and 2400 pg/ml.

15. The assay of claim 9 , wherein the liquid sample comprises serum or plasma prepared from a blood sample removed from a subject with a cancer.

16. The assay of claim 15 , wherein the liquid sample is a four-fold dilution of the serum or plasma preparation.

17. The assay of claim 15 , wherein the cancer is multiple myeloma.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2016
From: AYANOGLU, GULESI; DU, XIAOYAN; GUPTA, VINITA; LATERZA, OMAR; LIANG, LINDA; RIMMER, ERIC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 038427/0549 →